Tarazepide is used as a potent and selective CCK-A receptor antagonist to study cholecystokinin-mediated physiological processes; it reduces interdigestive and cephalic/early postprandial pancreatic secretion of protein and bicarbonate; it inhibits pancreatic protein secretion induced by intravenous or intraduodenal CCK-8; and it abolishes pancreatic secretory responses to leptin, making it a valuable tool for investigating the roles of CCK and sensory nerves in pancreatic exocrine function.